Aim To investigate the impact of pre-treatment serum total prostate-specific antigen (PSA) level on prevalence of prostate carcinoma detection in prostate core needle biopsy, and its correlation with established prognostic factors. Methods Prostate needle biopsy samples of 115 patients with available pre-treatment serum total PSA (tPSA) level were analysed. For all cases where morphology alone was insufficient, immunohistochemistry was performed using p63, CKHMW and AMACR antibody panel in order to confirm or exclude the existence of prostate carcinoma. Results Statistically significant positive correlation between serum total PSA values and prevalence of finding prostate carcinoma in needle biopsy specimens was found (p=0.011), as well as in the case when the patients were classified into groups according to tPSA levels (p=0.028). Serum total PSA values and levels (level groups) showed significant positive correlation with Gleason score (p=0.029 and p=0.036, respectively) and Grade Group of prostate carcinomas (p=0.044 and p=0.046, respectively). Sensitivity of the screening test by using 4 ng/mL as cut off value for tPSA was 94.12% (CI: 80.32-99.28%), specificity 8.64% (CI: 3.55-17.00%), positive predictive value 30.19% (CI: 21.65-39.87%) and negative predictive value 77.78% (CI: 39.99-97.19%). Conclusion The increase of serum tPSA value increases the likelihood of finding prostate cancer on needle biopsy specimens. Due to such findings and its positive correlation with a grade of prostate cancer, our study indicates that tPSA can still be considered as a useful tool both in detecting and predicting aggressiveness of prostate cancer.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwin E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–16.
3.
Magi-Galluzzi C. Prostate cancer: diagnostic criteria and role of immunohistochemistry. Mod Pathol. 2018;31:S12-21.
4.
Yu W, Zhou L. Early diagnosis of prostate cancer from the perspective of Chinese physicians. J Cancer. 2020;11:3264–73.
5.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.
6.
Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancermortality: the CAP randomized clinical trial. JAMA. 2018;319:883–95.
7.
Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implication. Diagn Pathol. 2016;11(25).
8.
Kryvenko ON, Epstein JI. Changes in prostate cancer grading: Including a new patient-centric grading system. Prostate. 2016;76:427–33.
9.
EM FJ, F L, M C, L M, M P, A Z, et al. Global cancer observatory: cancer today.
10.
Bratt O, Lilja H. Serum markers in prostate cancer detection. Curr Opin Urol. 2015;25:59–64.
11.
Fenton JJ, Weyerich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force JAMA. 2018;319:1914–31.
12.
Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25:431–6.
13.
Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010;116:4711–7.
14.
Orsted DD, Bojesen SE, Kamstrup PR, Nordestgaard BG. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality. Eur Urol. 2013;64:384–93.
15.
Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Urol J. 2009;6:182–8.
16.
Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng/ml) in predicting prostate cancer: is biopsy always required? J Urol. 2002;168:1990–3.
17.
USPST F, DC G, SJ C, DK O, K BD, AB C, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901–13.
18.
Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov H, SK B, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801–14.
19.
Nnabugwu U, EI U, FO O, F.O. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. Clin Interv Aging. 2016;11:961–6.
20.
Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol. 2007;177:505–9.
21.
Loeb S, Sutherland DE, D’Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology. 2008;72:1116–20.
22.
Milonas D, Smaiyse D, Jievaltas M. Factors predicting Gleason score 6 upgrading after radical prostatectomy. Cent European J Urol. 2011;64:205–8.
23.
Jayapradeep DP, Prakash VB, Philipose TR, Pai MR. Histomorphological correlation of PSA levels in prostatic carcinoma. National J Lab Med. 2017;6:28–32.
24.
Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111:753–60.
25.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428–35.
26.
Barakzai MA. Prostatic adenocarcinoma: a grading from Gleason to the new grade-group system: A Historical and Critical Review. Asian Pac J Cancer Prev. 2019;20:661–6.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
